Breaking Biotech

016 - Why I sold Gilead. Closed-loop system for Type 2 Diabetics??


Listen Later

-Gilead loses 3 executives in the last 6 months, but that's not why I sold! -New research suggests that closed-loop insulin delivery-glucose monitoring keeps type 2 diabetics in range better than conventional therapy Follow me @matthewlepoire this is not investment advice
...more
View all episodesView all episodes
Download on the App Store

Breaking BiotechBy Matthew Lepoire

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.9

4.9

24 ratings